CBT Pharmaceuticals, Inc.
5976 W. Las Positas Boulevard
About CBT Pharmaceuticals, Inc.
CBT Pharma is an emerging life sciences oncology company focused on developing innovative medicines targeting the growth and proliferation of cancer cells for which available treatments are inadequate. The company was founded in 2016 with headquarters in California with global partners and a subsidiary in Asia. Our pipeline is comprised of four development-stage assets – an oral agent that specifically targets cancer metastasis, a pre-clinical candidate that targets uncontrolled growth signaling pathways, and two investigational products that restore the body’s immune system to recognize and kill cancer cells.
Founders: Guo-Liang Yu and Sanjeev Redkar
CEO: Sanjeev Redkar, PhD, MBA
Executive Vice President and COO: Gavin Choy, PharmD, MBA
10 articles with CBT Pharmaceuticals, Inc.
Based in Santa Clara, California, CBT Pharma was spun out of Crown Bioscience with four development-stage assets in the oncology space.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
CBT Pharma Presents Data Demonstrating Anti-Tumor Activity of its PD-L1 Immunotherapy Antibody, CBT-502 at the AACR-NCI-EORTC International Conference on Molecular Target and Cancer Therapeutics
CBT Pharma presented preclinical data which showed that CBT-502 efficiently inhibited binding of PD-L1 with no binding to PD-L2, CD28, ICOS or CTLA4.
CBT Pharma Announces First U.S. Patient Dosed In Phase 1 Clinical Trial Of C-Met Inhibitor, CBT-101, For Advanced Solid Tumors With C-Met Dysregulation
CBT Pharma today announced that the first subject has been dosed in the Phase I multi-center study, CBT-101-01 which is an important milestone for CBT and its employees.
CBT Pharma Appoints Nationally Recognized Leaders In Oncology To Newly Established Scientific Advisory Board
CBT Pharma Presents Data Demonstrating Anti-Tumor Activity Of Its Highly Specific C-MET Inhibitor, Bozitinib (CBT-101), At AACR Annual Meeting 2017
CBT Pharma Release: First-in-Human Genolimzumab Phase I Study Initiated To Assess Safety And Preliminary Efficacy In Patients With Select Advanced Solid Tumors
CBT Pharma Presents Data Demonstrating Anti-Tumor Activity Of Its Programmed Death-1 Antibody, CBT-501, At ASCO-SITC Clinical Oncology Symposium
CBT Pharma Closes $9.75 Million Series A Financing Led By OrbiMed For Development Of Oncology Pipeline